Holen Sie sich die Stockscreener-App
0.354
4.66%
-0.0173
Schlusskurs vom Vortag:
$0.3713
Offen:
$0.3607
24-Stunden-Volumen:
350.85K
Relative Volume:
0.26
Marktkapitalisierung:
$2.20M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-22.56M
KGV:
-0.1834
EPS:
-1.93
Netto-Cashflow:
$-16.12M
1W Leistung:
-9.99%
1M Leistung:
-73.18%
6M Leistung:
-84.27%
1J Leistung:
+30.63%
1-Tages-Spanne:
$0.3241
$0.377
1-Wochen-Bereich:
$0.3241
$0.3933
52-Wochen-Spanne:
$0.231
$4.3785
Cyclacel Pharmaceuticals Inc Stock (CYCC) Company Profile
Firmenname
Cyclacel Pharmaceuticals Inc
Sektor
Branche
Telefon
908-517-7330
Adresse
200 CONNELL DRIVE, BERKELEY HEIGHTS, NJ
Vergleichen Sie CYCC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| CYCC | 0.354 | 2.20M | 0 | -22.56M | -16.12M | -1.93 |
| VRTX | 449.93 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 745.30 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 595.77 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 246.16 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 108.17 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Cyclacel Pharmaceuticals Inc Stock (CYCC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
| 2020-04-27 | Fortgesetzt | ROTH Capital | Buy |
| 2018-09-07 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2015-10-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2010-02-04 | Eingeleitet | Roth Capital | Buy |
| 2009-10-28 | Eingeleitet | Merriman | Buy |
| 2008-08-12 | Eingeleitet | Piper Jaffray | Buy |
| 2008-03-12 | Bestätigt | Cantor Fitzgerald | Buy |
| 2008-03-12 | Bestätigt | Collins Stewart | Buy |
| 2008-03-12 | Bestätigt | Needham & Co | Buy |
| 2007-11-27 | Bestätigt | Cantor Fitzgerald | Buy |
| 2007-08-10 | Bestätigt | Cantor Fitzgerald | Buy |
| 2007-06-04 | Bestätigt | Needham & Co | Buy |
| 2007-04-23 | Eingeleitet | Lazard Capital | Buy |
| 2007-04-10 | Eingeleitet | Cantor Fitzgerald | Buy |
Alle ansehen
Cyclacel Pharmaceuticals Inc Aktie (CYCC) Neueste Nachrichten
Cyclacel stock plunges to 52-week low of $0.32 amid market challenges - Investing.com
Cyclacel Pharmaceuticals Reports Q3 2024 Financial Results - TipRanks
Cyclacel Pharmaceuticals Third Quarter 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Armistice Capital, LLC Increases Stake in Cyclacel Pharmaceutica - GuruFocus.com
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals, Inc. (CYCC) Reports Q3 Loss - MSN
Cyclacel stock plunges to 52-week low of $0.37 amid market challenges - Investing.com Canada
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds - The Manila Times
Cyclacel Pharmaceuticals Raises $2.1M Through Warrant Exercise Deal at $0.415 Per Share | CYCC Stock News - StockTitan
Cyclacel Pharmaceuticals appoints new auditor By Investing.com - Investing.com Australia
Cyclacel Pharmaceuticals appoints new auditor - Investing.com India
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update - The Manila Times
Cyclacel Faces Delisting Risk Despite 67% Lower Q3 Loss; Cash Concerns Mount | CYCC Stock News - StockTitan
(CYCCP) Technical Pivots with Risk Controls - Stock Traders Daily
A Data-Based Look At Cyclacel Pharmaceuticals Inc (CYCC) - Stocks Register
Cyclacel stock plunges to 52-week low at $0.6 amid market challenges - Investing.com
Cyclacel stock plunges to 52-week low at $0.74 amid market challenges - Investing.com India
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule - The Manila Times
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - ForexTV.com
Nasopharyngeal Cancer Market Report: Growth Forecast and Key - openPR
Sangamo Therapeutics, Cyclacel Pharma, GE Aerospace: 3 Stocks Retailers Are Most Bullish Tuesday Afternoon - Barchart
Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) Stock Sentiment: What’s Wall Street Saying? - Stocks Register
CYCCPCyclacel Pharmaceuticals, Inc. 6% Cnvrtbl. Prfrd. Stock Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals (CYCC) Price Target Increased by 11.56% to 13.94 - MSN
Cyclacel stock plunges to 52-week low, touches $0.8 By Investing.com - Investing.com Australia
Cyclacel stock plunges to 52-week low, touches $0.8 - Investing.com
CYCCCyclacel Pharmaceuticals, Inc Latest Stock News & Market Updates - StockTitan
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium - The Manila Times
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges - Investing.com Australia
Cyclacel stock plunges to 52-week low at $0.95 amid market challenges By Investing.com - Investing.com South Africa
Cyclacel Pharmaceuticals Announces Completion of Enrollment in the Biomarker-Enriched Patient Cohort of Its Phase 2 Study - ForexTV.com
Entero Therapeutics (NASDAQ:ENTO) Stock Quotes, Forecast and News Summary - Benzinga
(CYCCP) Trading Report - Stock Traders Daily
Cyclacel Pharmaceuticals (CYCC) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - MSN
Cyclacel halts dividend on preferred stock - Investing.com
Cyclacel halts dividend on preferred stock By Investing.com - Investing.com Canada
Cyclacel Pharmaceuticals Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference - ForexTV.com
Cyclacel Pharmaceuticals Confirms It Has Filed an Appeal to Nasdaq Staff Delisting Letter - ForexTV.com
Cyclacel Pharmaceuticals May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Benzinga
Finanzdaten der Cyclacel Pharmaceuticals Inc-Aktie (CYCC)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):